94 related articles for article (PubMed ID: 2040181)
1. Stable renal function and benign course in azotemic diabetics treated with erythropoietin for one year.
Brown CD; Friedman EA
Contrib Nephrol; 1991; 88():182-9; discussion 190-1. PubMed ID: 2040181
[No Abstract] [Full Text] [Related]
2. Does anemia correction by rHuEPO improve uremic cardiopathy?
Carletti P; Bibiano L; Boggi R; Taruscia D; Mioli V
Kidney Int Suppl; 1993 Jun; 41():S70-1. PubMed ID: 8320949
[TBL] [Abstract][Full Text] [Related]
3. Treatment of azotemic, nonoliguric, anemic patients with human recombinant erythropoietin raises whole-blood viscosity proportional to hematocrit.
Brown CD; Kieran M; Thomas LL; Zhao ZH; Larsen R; Friedman EA
Nephron; 1991; 59(3):394-8. PubMed ID: 1758527
[TBL] [Abstract][Full Text] [Related]
4. Clinical and blood rheologic stability in erythropoietin-treated predialysis patients.
Brown CD; Friedman EA
Am J Nephrol; 1990; 10 Suppl 2():29-33. PubMed ID: 2260615
[TBL] [Abstract][Full Text] [Related]
5. Role of rHuEPO in treatment of uremic anemia prior to end-stage renal disease.
Koene RA; Frenken LA
Kidney Int Suppl; 1992 Oct; 38():S142-7. PubMed ID: 1405365
[No Abstract] [Full Text] [Related]
6. Erythropoietin in diabetic macular edema and renal insufficiency.
Friedman EA; Brown CD; Berman DH
Am J Kidney Dis; 1995 Jul; 26(1):202-8. PubMed ID: 7611253
[TBL] [Abstract][Full Text] [Related]
7. Treating azotemia-induced anemia with erythropoietin improves diabetic eye disease.
Friedman EA; L'Esperance FA; Brown CD; Berman DH
Kidney Int Suppl; 2003 Nov; (87):S57-63. PubMed ID: 14531775
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and tolerance of treatment with recombinant-human erythropoietin in chronic renal failure (pre-dialysis) patients.
Frenken LA; Verberckmoes R; Michielsen P; Koene RA
Nephrol Dial Transplant; 1989; 4(9):782-6. PubMed ID: 2516609
[TBL] [Abstract][Full Text] [Related]
9. Cardiovascular hemodynamic effects of correction of anemia of chronic renal failure with recombinant-human erythropoietin.
Schwartz AB; Prior JE; Mintz GS; Kim KE; Kahn SB
Transplant Proc; 1991 Apr; 23(2):1827-30. PubMed ID: 2053168
[TBL] [Abstract][Full Text] [Related]
10. Effects of the evening i.v. administration of erythropoietin in haemodialyzed patients.
Buemi M; Allegra A; Laganà A; Aloisi C; Privitera M; Morabito N; Frisina N
Riv Eur Sci Med Farmacol; 1993; 15(5-6):195-7. PubMed ID: 7761669
[TBL] [Abstract][Full Text] [Related]
11. Recombinant human erythropoietin in renal transplant recipients with renal anemia.
Traindl O; Barnas U; Franz M; Falger S; Klauser R; Kovarik J; Graf H
Clin Transplant; 1994 Feb; 8(1):45-8. PubMed ID: 8136567
[TBL] [Abstract][Full Text] [Related]
12. [Hemo-rheologic changes following treatment with human recombinant erythropoietin in chronic hemodialysis patients].
Melappioni M; Giansanti R; Boemi M; Baldassari M; Baldini S; Pierangeli T; Radicioni R; Fumelli P; Panichi N
Minerva Urol Nefrol; 1992; 44(2):155-9. PubMed ID: 1411865
[TBL] [Abstract][Full Text] [Related]
13. Recombinant human erythropoietin therapy. Part I: clinical issues.
Semin Nephrol; 1989 Mar; 9(1 Suppl 1):1-34. PubMed ID: 2928605
[No Abstract] [Full Text] [Related]
14. Early intervention with recombinant human erythropoietin therapy.
Teehan BP; Benz RL; Sigler MH; Brown JM
Semin Nephrol; 1990 Mar; 10(2 Suppl 1):28-34. PubMed ID: 2192414
[No Abstract] [Full Text] [Related]
15. Rate of progression of chronic renal failure in predialysis patients treated with erythropoietin.
Abels R
Semin Nephrol; 1990 Mar; 10(2 Suppl 1):20-5. PubMed ID: 2192413
[No Abstract] [Full Text] [Related]
16. Subcutaneous low doses of recombinant human erythropoietin in predialysis patients do not interfere with the progression of renal failure.
Savica V; Costantino G; Monardo P; Bellinghieri G
Am J Nephrol; 1995; 15(1):10-4. PubMed ID: 7872358
[TBL] [Abstract][Full Text] [Related]
17. [Results of treating uremia anemia with human recombinant erythropoietin].
Litwin M; Grenda R; Jelonek A
Pol Tyg Lek; 1994 Feb 7-14; 49(6-7):132-4. PubMed ID: 8090664
[TBL] [Abstract][Full Text] [Related]
18. Treatment of the anaemia of end-stage renal disease with recombinant human erythropoietin.
Verbeelen D; Hauglustaine D; Sennesael J
Neth J Med; 1988 Aug; 33(1-2):60-7. PubMed ID: 3247012
[No Abstract] [Full Text] [Related]
19. Importance of iron status monitoring during erythropoietin treatment in uremic predialysis patients.
Rutkowski B; Debska-Slizień A; Biedunkiewicz B; Bułło B
Ann Univ Mariae Curie Sklodowska Med; 1994; 48 Suppl 3():17-21. PubMed ID: 8192528
[TBL] [Abstract][Full Text] [Related]
20. Serum erythropoietin and creatinine concentrations as predictive factors for response to recombinant human erythropoietin treatment in anaemic tumour patients on chemotherapy.
Fjornes T; Wiedemann GJ; Sack K; Jelkmann W
Oncol Rep; 1998; 5(1):81-6. PubMed ID: 9458299
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
